Insulin Like Growth Factor I Receptor Function in Estrogen Receptor Negative Breast Cancer

Abstract

A recent CALGB 9344 trial (INT 048) examined the addition of paclitaxel therapy to standard chemotherapy regimes. The results of this trial demonstrated addition of paclitaxel to standard adjuvant therapy, doxorubicin and cyclophosphamide, was associated with proportional reductions in both relapse risk and risk of death. Subgroup analyses were conducted to identify tumor characteristics that would predict response to paclitaxel treatment. These analyses showed that the benefit of paclitaxel treatment was restricted to ER- patients (CALGB central statistics office), indicating that there was an association between estrogen receptor status and paclitaxel sensitivity. The results reported here demonstrate that the differences in growth between ER+ and ER- breast cancer cells reflect the differential sensitivity to paclitaxel observed both in vitro and in the clinic.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2000
Accession Number
ADA383054

Entities

People

  • Michele Dougherty

Organizations

  • Georgetown University

Tags

DTIC Thesaurus Topics

  • Apoptosis
  • Breast Cancer
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Chemotherapy
  • Estrogens
  • Growth Factors
  • Hormones
  • Laboratory Animals
  • Materials
  • Neoplasms
  • Recombinant Dna
  • Sensitivity
  • Standards
  • Statistics
  • Tumor Cell Line

Fields of Study

  • Medicine

Readers

  • Breast cancer cell signaling and growth regulation.
  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.
  • Oncology (Cancer Research).